227 related articles for article (PubMed ID: 27363974)
1. Treatment for cirrhotic ascites.
Kawaratani H; Fukui H; Yoshiji H
Hepatol Res; 2017 Feb; 47(2):166-177. PubMed ID: 27363974
[TBL] [Abstract][Full Text] [Related]
2. Management of refractory cirrhotic ascites: challenges and solutions.
Fukui H; Kawaratani H; Kaji K; Takaya H; Yoshiji H
Hepat Med; 2018; 10():55-71. PubMed ID: 30013405
[TBL] [Abstract][Full Text] [Related]
3. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
4. Management of ascites and hepatorenal syndrome.
Piano S; Tonon M; Angeli P
Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
[TBL] [Abstract][Full Text] [Related]
5. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.
Gallo A; Dedionigi C; Civitelli C; Panzeri A; Corradi C; Squizzato A
J Transl Int Med; 2020 Dec; 8(4):220-236. PubMed ID: 33511049
[TBL] [Abstract][Full Text] [Related]
6. [Surgical approach to posthepatitic cirrhotic patient today].
Meriggi F; Forni E
G Chir; 1996; 17(6-7):370-8. PubMed ID: 9272983
[TBL] [Abstract][Full Text] [Related]
7. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
[TBL] [Abstract][Full Text] [Related]
8. [New therapeutic paradigm and concepts for patients with cirrhotic refractory ascites].
Wang SZ; Ding HG
Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):249-253. PubMed ID: 28494541
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary application of transjugular intrahepatic portosystemic shunt in individualized treatment of patients with cirrhotic portal hypertension complicated with refractory ascites and variceal hemorrhage].
Jiang MM; Xu H; Zhang QQ; Wei N; Xu W; Cui YF; Liu HT; Zu MH; Wang WL; Gao ZK
Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3737-3740. PubMed ID: 31874500
[No Abstract] [Full Text] [Related]
10. Management of cirrhotic ascites: Seven-step treatment protocol based on the Japanese evidence-based clinical practice guidelines for liver cirrhosis 2020.
Yoshiji H
Hepatol Res; 2023 Jun; ():. PubMed ID: 37332123
[TBL] [Abstract][Full Text] [Related]
11. [Complications of liver cirrhosis - pharmaceutical versus interventional therapy].
Sturm L; Rössle M; Schultheiß M
Dtsch Med Wochenschr; 2019 Sep; 144(18):1259-1266. PubMed ID: 31514216
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ascites: old and new remedies.
Inturri P; Graziotto A; Rossaro L
Dig Dis; 1996; 14(3):145-56. PubMed ID: 8861522
[TBL] [Abstract][Full Text] [Related]
13. The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis.
Iannone G; Pompili E; De Venuto C; Pratelli D; Tedesco G; Baldassarre M; Caraceni P; Zaccherini G
J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592162
[TBL] [Abstract][Full Text] [Related]
14. Current concepts in the management of refractory cirrhotic ascites.
Oguntona SA; Alebiosu CO
Niger J Med; 2006; 15(3):197-202. PubMed ID: 17111742
[TBL] [Abstract][Full Text] [Related]
15. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.
Habib S; Boyer TD
Therap Adv Gastroenterol; 2012 May; 5(3):189-97. PubMed ID: 22570679
[TBL] [Abstract][Full Text] [Related]
17. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
18. Ascites: pathogenesis and therapeutic principles.
Møller S; Henriksen JH; Bendtsen F
Scand J Gastroenterol; 2009; 44(8):902-11. PubMed ID: 19479632
[TBL] [Abstract][Full Text] [Related]
19. [Current ascites therapy].
Ochs A
Praxis (Bern 1994); 1997 Jan; 86(4):94-7. PubMed ID: 9064726
[TBL] [Abstract][Full Text] [Related]
20. [Role of surgical therapy in the treatment of refractory ascites].
Pisani Ceretti A; Intra M; Borzio M; Santambrogio R; Opocher E; Ballarini C; Cordovana A; Motta R; Spina GP
Minerva Chir; 1997 Nov; 52(11):1339-48. PubMed ID: 9489332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
